ENZC 0.00 Enzolytics Inc.
| Range: | 0.0014-0.032 | Vol Avg: | 9180431 | Last Div: | 0 | Changes: | 0 |
| Beta: | 0.93 | Cap: | 0.01B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Wed Apr 08 2009 | Empoloyees: | 1 | ||
| CUSIP: | 294112107 | CIK: | ISIN: | US2941121079 | Country: | US | |
| CEO: | Steven Sharabura | Website: | https://enzolytics.com | ||||
Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow